International Stem Cell (OTCMKTS:ISCO – Get Free Report) announced its earnings results on Thursday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports. The firm had revenue of $2.67 million for the quarter.
International Stem Cell Stock Performance
Shares of ISCO stock opened at $0.35 on Friday. The stock’s fifty day moving average is $0.22 and its two-hundred day moving average is $0.18. The firm has a market capitalization of $2.80 million, a P/E ratio of -4.38 and a beta of -0.03. International Stem Cell has a fifty-two week low of $0.12 and a fifty-two week high of $0.48.
About International Stem Cell
International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.
In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.
Further Reading
- Five stocks we like better than International Stem Cell
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
- AirJoule Technologies: Short Squeeze Setup Amid Rising Risks
- MarketBeat Week in Review – 08/10 – 08/14
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.
